Emyria Ltd (AU:EMD) has released an update.
Emyria Ltd, specializing in mental health treatments, has proudly announced that its Empax Centre will be a key site for a pivotal clinical trial by Transcend Therapeutics. The trial will assess the novel methylone treatment for PTSD, depression, and anxiety, highlighting Emyria’s commitment to improving mental health outcomes and showcasing its advanced research capabilities. Additionally, the company will receive market-rate compensation for its specialist services provided during the trial.
For further insights into AU:EMD stock, check out TipRanks’ Stock Analysis page.
